0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Improving the reporting of clinical trials of infertility treatments (IMPRINT): modifying the CONSORT statement†‡.

      Human Reproduction (Oxford, England)

      Oxford University Press (OUP)

      infertility trial, modification, IMPRINT, CONSORT, reporting

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Clinical trials testing infertility treatments often do not report on the major outcomes of interest to patients and clinicians and the public (such as live birth) nor on the harms, including maternal risks during pregnancy and fetal anomalies. This is complicated by the multiple participants in infertility trials which may include a woman (mother), a man (father), and result in a third individual if successful, their offspring (child), who is also the desired outcome of treatment. The primary outcome of interest and many adverse events occur after cessation of infertility treatment and during pregnancy and the puerperium, which create a unique burden of follow-up for clinical trial investigators and participants. In 2013, because of the inconsistencies in trial reporting and the unique aspects of infertility trials not adequately addressed by existing Consolidated Standards of Reporting Trials (CONSORT) statements, we convened a consensus conference in Harbin, China, with the aim of planning modifications to the CONSORT checklist to improve the quality of reporting of clinical trials testing infertility treatment. The consensus group recommended that the preferred primary outcome of all infertility trials is live birth (defined as any delivery of a live infant ≥20 weeks gestations) or cumulative live birth, defined as the live birth per women over a defined time period (or number of treatment cycles). In addition, harms to all participants should be systematically collected and reported, including during the intervention, any resulting pregnancy, and during the neonatal period. Routine information should be collected and reported on both male and female participants in the trial. We propose to track the change in quality that these guidelines may produce in published trials testing infertility treatments. Our ultimate goal is to increase the transparency of benefits and risks of infertility treatments to provide better medical care to affected individuals and couples.

          Related collections

          Most cited references 12

          • Record: found
          • Abstract: not found
          • Article: not found

          CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Practice bulletin #33: diagnosis and management of preeclampsia and eclampsia

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              A practical classification of newborn infants by weight and gestational age

                Bookmark

                Author and article information

                Journal
                25217611
                4481576
                10.1093/humrep/deu218

                infertility trial, modification, IMPRINT, CONSORT, reporting

                Comments

                Comment on this article